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Background: Accumulation of beta-amyloid and neuroinflammation trigger Alzheimer’s disease. We previously
found that lipopolysaccharide (LPS) caused neuroinflammation with concomitant accumulation of beta-amyloid
peptides leading to memory loss. A variety of anti-inflammatory compounds inhibiting nuclear factor kappaB
(NF-κB) activation have showed efficacy to hinder neuroinflammation and amyloidogenesis. We also found that
bee venom (BV) inhibits NF-κB.
Methods: A mouse model of LPS-induced memory loss used administration of BV (0.8 and 1.6 μg/kg/day, i.p.)
to ICR mice for 7 days before injection of LPS (2.5 mg/kg/day, i.p.). Memory loss was assessed using a Morris
water maze test and passive avoidance test. For in vitro study, we treated BV (0.5, 1, and 2 μg/mL) to astrocytes
and microglial BV-2 cells with LPS (1 μg/mL).
Results: We found that BV inhibited LPS-induced memory loss determined by behavioral tests as well as cell
death. BV also inhibited LPS-induced increases in the level of beta-amyloid (Aβ), β-and γ-secretases activities,
NF-κB and its DNA-binding activity and expression of APP, and BACE1 and neuroinflammation proteins (COX-2,
iNOS, GFAP and IBA-1) in the brain and cultured cells. In addition, pull-down assay and molecular modeling
showed that BV binds to NF-κB.
Conclusions: BV attenuates LPS-induced amyloidogenesis, neuroinflammation, and therefore memory loss via
inhibiting NF-κB signaling pathway. Thus, BV could be useful for treatment of Alzheimer’s disease.
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NeuroinflammationIntroduction
Alzheimer’s disease (AD) is the most common neurode-
generative disease due to loss of neurons in the brain.
Typical early symptoms of AD patients are losing their
ability to learn new information and then loss of both
declarative and non-declarative memory [1]. AD is
generally known to be correlated with accumulation of
beta-amyloid (Aβ) peptides which is produced from amyl-
oid precursor protein (APP) [2, 3]. APP is decomposed* Correspondence: sondj1@chungbuk.ac.kr; jinthong@chungbuk.ac.kr
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carboxy-terminal 99 amino acid (C99) protein by β-site
APP cleaving enzyme (β-secretase; BACE1), and then
γ-secretase produces Aβ and amyloid intracellular do-
main (ACID) from C99 [4]. AD patients have showed a
high level of Aβ output and aggregative Aβ [5].
Lipopolysaccharide (LPS) can trigger neuroinflamma-
tion and influence amyloidogenesis in neuronal cells.
LPS activates inflammatory cells such as astrocytes and
microglia cells in the brain, thus enhancing neuroinflam-
mation [6–9]. LPS also induces accumulation of Aβ
through increased cleavage of APP by increasing BACE1
and γ-secretase activation [9, 10]. Nuclear factor kappaB
(NF-κB) can be activated by LPS, and then inducesdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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factor-a (TNF-α interleukins (IL-1β, IL-6, and IL-18), indu-
cible nitric oxide synthase (iNOS), and cyclooxygenase-2
(COX-2) [11]. NF-κB also induces decomposition of
APP by activating BACE1. BACE1 promoter activity and
BACE1 transcription are increased by activating NF-κB
because the BACE1 promoter has a NF-κB-binding site
[12, 13]. Therefore, inhibiting NF-κB pathways could
interrupt generation of Aβ as well as neuroinflamma-
tion [14]. A variety of anti-inflammatory compounds
inhibiting NF-κB activation, such as (-)-epigallocatechin-3-
gallate (EGCG), thiacremonone, and N-adamantyl-4-
methylthiazol-2-amine (KHG26693), have showed efficacy
to hinder neuroinflammation and amyloidogenesis, and
thus reduce memory loss [14–17].
Bee venom (BV) has been used as a traditional cure in
oriental countries [18]. Various diseases, such as arth-
ritis, rheumatism, and cancer have been treated by BV
[19]. BV consists of various active components, for ex-
ample: peptides (e.g., melittin, apamin, adolapin, and the
mast cell degranulating peptide; MCD), enzymes (e.g.,
phospholipase A2; PLA2, hyaluronidase, glucosidase),
and biogenic amines (e.g., histamines, dopamine, nor-
epinephrine) [19]. Several research groups have proved
the anti-inflammatory effect of BV in several disease
models such as a mouse model of Parkinson’s disease,
Freund’s adjuvant-induced rheumatoid arthritis (RA)
model, and cholecystokinin octapeptide-induced acute
pancreatitis rat model [20–22]. BV and its major compo-
nent melittin inhibited LPS and TNF-α-induced NF-κB
activation by interrupting p50 translocation through
interaction with sulfhydryl residue of p50 or IκB kinases
(IKKα and IKKβ) [23, 24]. Our study also showed that
BV prevented LPS-induced nitric oxide (NO) and pros-
taglandin E2 (PGE2) production through inactivation of
NF-κB in RAW 264.7 cells [25]. In this study, we investi-
gated whether BV inhibits neuroinflammation response
and amyloidogenesis through inactivation of NF-κB
in vitro and in vivo, and thus reduces memory lose by LPS.
Materials and methods
Materials
BV was purchased from You-Miel Bee Venom Ltd.
(Hwasoon, Jeonnam, Korea). The composition of the BV
was as follows: 45–50 % melittin, 2.5–3 % mast cell
degranulating peptide, 12 % phospholipase A2, 1 %
lysophospholipase A, 1–1.5 % histidine, 4–5 % 6-pentyl
a-pyrone lipids, 0.5 % secarpin, 0.1 % tertiapin, 0.1 %
procamine, 1.5–2 % hyaluronidase, 2–3 % amine, 4–5 %
carbohydrate, and 19–27 % of others, including protease
inhibitor, glucosidase, invertase, acid phosphomonoester-
ase, dopamine, norepinephrine, and unknown amino
acids, with 99.5 % purity. Melittin was purchased from
Sigma-Aldrich (St. Louis, MO).Animals and treatments
Seven- to eight-week male imprinting control region
(ICR) mice (Daehan Biolink, Chungcheongbuk-do, Korea)
were maintained and handled in accordance with the hu-
mane animal care and use guidelines of the Korean FDA.
All experiments were approved and carried out according
to the Guidelines for the Care and Use of Animals
[Animal Care Committee of Chungbuk National University,
Korea (CBNUA-436-12-02)]. All efforts were made to
minimize animal suffering, to reduce the number of
animals used. All mice were housed in a room with
automatic control of temperature (21~25 °C), relative
humidity (45–65 %), and light-dark (12–12 h) cycles.
To induce neuroinflammatory cognitive impairment
model, LPS (2.5 mg/kg) was administrated intraperi-
toneally [26]. The LPS (serotype O55:B5, Sigma, St.
Louis, MO. USA, final concentration of 1 mg/mL)
was dissolved, and aliquots in distilled water (DW)
were stored at −20 °C until use. The BV (final con-
centration of 1 mg/mL) was dissolved in DW, and ali-
quots were stored at −20 °C until use. These are the
following four groups: (I) saline + saline group (control);
(II) saline + LPS group (LPS); (III) BV (0.8 μg/kg) + LPS
group (BV 0.8); and (IV) BV (1.6 μg/kg) + LPS group
(BV 1.6), and each group was assigned to eight mice.
First, intraperitoneal (i.p.) injection (0.8 μg/kg, 1.6 μg/kg)
of BV and i.p. injection (2.5 mg/kg) of LPS or control
(saline) was administered after 30 min. The doses of BV
were the same with the previous study [23]. This step
was performed daily for seven days. And then, the behav-
ioral tests of learning and memory capacity were assessed
using two separate tests (water maze and passive avoid-
ance test). After training once beforehand (day 0), the
test was performed in the date of the first, third, and sev-
enth day (Fig. 1a).
Morris water maze test
The water maze test is also a commonly accepted
method for memory test, and we performed this test as
described by Morris et al. [27]. Maze testing was fulfilled
by the SMART-CS (Panlab, Barcelona, Spain) program
and equipment. A circular plastic pool (height; 35 cm,
diameter; 100 cm) was filled with squid-ink water kept
at 22–25 °C. An escape platform (height; 14.5 cm,
diameter; 4.5 cm) was submerged 1–1.5 cm below the
surface of the water in position. On training trials, the
mice were placed in a pool of water and allowed to
remain on the platform for 10 s and were then
returned to the cage. The mice that did not find the
platform within 120 s were placed on the platform for
3 s at the end of the trial. Then mice stay on the plat-
form for seven more seconds. These trials were per-
formed on a single platform and in three starting
positions of rotational starting. Escape latency, escape
Fig. 1 Timeline depicting the treatment of BV and assessments of cognitive functions of mice (a). Arrow heads represent days on which
acquisition tests were conducted. Inhibitory effect of BV on LPS-induced memory defects. Mice were treated with BV (0.8 and 1.6 μg/kg, i.p.) after
20-min treatment of LPS (2.5 mg/kg, i.p.). The Morris water maze tests and passive avoidance tests were performed as described in the Methods
section. LPS injection elongates escape distance (b) and time (c) without affecting average swimming speed (d). LPS decreases the latency to
enter the dark compartment. The memory deficit induced by LPS was attenuated by BV treatment (e). Values are presented as mean ± S.E. from
eight mice. #p < 0.05 compared to control, *p < 0.05 compared to LPS
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each mouse was monitored by a camera above the
center of the pool connected to a SMART-LD pro-
gram (Panlab, Barcelona, Spain).
Passive avoidance performance test
The passive avoidance test is generally accepted as a
simple method for memory testing. The passive avoid-
ance response was determined using a “step-through”
apparatus (Med Associates Inc, Vermont, USA) that is
consisted of an illuminated and a dark compartment
(each 20.3 × 15.9 × 21.3 cm) adjoining each other
through a small gate with a grid floor, 3.175-mm stain-
less steel-rod set 8 mm apart. On the first day, the mice
were placed in the illuminated compartment facing away
from the dark compartment for the training trial. When
the mice moved completely into the dark compartment,
they received an electric shock (2 mA, 3-s duration).Then the mice were returned to their case. From train-
ing day after 1, 3, and 7 days, the mice were placed in
the illuminated compartment and the latency period to
enter the dark compartment defined as “retention” was
measured. The time when the mice entered into the
dark compartment was recorded and described as step-
through latency. The retention trials were set at a limit
of 10 min of cutoff time.
Brain collection and preservation
After behavioral tests, mice were perfused with
phosphate-buffered saline (PBS, pH 7.4) under inhaled
diethyl ether anesthetization. The brains were immedi-
ately pulled from the skull, cut, and divided into the left
brain and right brain. One hippocampus was removed
and stored at −80 °C, the others were fixed in 4 % para-
formaldehyde for 48 h at 4 °C and transferred to 30 %
sucrose solutions.
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Astrocytes were prepared from the cerebral cortex of rat
embryos (E18). After removal of the exception of the
cerebral cortex, the cerebral cortex was dissociated into
a single-cell suspension by trypsinization and mechanical
disruption. The cells were seeded on T-75 culture flasks
and incubated in Dulbecco’s modified eagle medium
(DMEM/F-12) (Invitrogen, Carlsbad, CA) containing
10 % fetal bovine serum (FBS) (Invitrogen). The culture
medium was replaced at every 3 days thereafter. After
10–12 days, the cultures became confluent, and loosely
attached microglia and oligodendrocyte precursor cells
were removed from the cell monolayer through use of a
shaking incubator (37 °C, 350 RPM, 2–4 h). Astrocytes
were subsequently detached using trypsin-EDTA and
plated into 100-mm cell culture dishes. The percentage
of astrocytes in our culture system is more than 95 %.
Microglial BV-2 cells were maintained with serum-
supplemented culture media of DMEM supplemented
with FBS (10 %) and penicillin (100 units/ml). The
microglial BV-2 cells were incubated in the culture
medium in a humidified incubator at 37 °C and 5 %
CO2. The cultured cells were treated simultaneously
with LPS (1 μg/ml) and several concentrations (0.5,
1, 2 μg/ml) of BV dissolved in distilled water, and
the cells were harvested after 48 h.
Immunohistochemical staining
After being transferred to 30 % sucrose solutions, brains
were cut into 30-μm sections by using a cryostat micro-
tome (Leica CM 1850; Leica Microsystems, Seoul,
Korea). After two washes in PBS (pH 7.4) for each 10
min, endogenous peroxidase activity was quenched by
incubating the samples in 3 % hydrogen peroxide in PBS
for 20 min, and two washes in PBS for each 10 min. The
brain sections were blocked for 1 h in 5 % bovine serum
albumin (BSA) solution and incubated overnight at 4 °C
with a mouse polyclonal antibody against glial fibrillary
acidic protein (GFAP) (1:300; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA), inducible nitric oxide syn-
thase (iNOS) (1:300; Novus Biologicals, Inc., Littleton), a
rabbit polyclonal antibody against cyclooxygenase-2
(COX-2) (1:300; Cell Signaling Technology, Inc., Beverly,
MA, USA), and a goat polyclonal antibody against ionize
calcium-binding adapter molecule 1 (IBA-1) (1:300;
Abcam, Inc., Cambridge, MA, USA). After incubation
with the primary antibodies, brain sections were washed
thrice in PBS for each 10 min. After washing, brain sec-
tions were incubated for 1–2 h at room temperature
with the biotinylated goat anti-rabbit or goat anti-mouse
or donkey anti-goat IgG-horseradish peroxidase (HRP)
secondary antibodies (1:500; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA). Brain sections were washed
thrice in PBS for each 10 min and visualized bychromogen DAB (Vector Laboratories) reaction for up
to 10 min. Finally, brain sections were dehydrated in
ethanol, cleared in xylene, mounted with Permount
(Fisher Scientific, Hampton, NH), and evaluated on a
light microscopy (Olympus, Tokyo, Japan) (×50 or ×200).
Fluorescence microscopy
The fixed cells and brain sections were exposed to the
following primary antibodies: GFAP (1:100, Santa Cruz
Biotechnology Inc. Santa Cruz, CA, USA), IBA-1
(Abcam, Inc., Cambridge, MA, USA), and Aβ1-42 (1:100,
Cell Signaling Technology, Inc. Beverly, MA) at room
temperature for 2 h. After incubation, the cells were
washed twice with ice-cold PBS and incubated with an
anti-rabbit or mouse or goat secondary antibody conju-
gated to Alexa Fluor 488 or 568 (Invitrogen-Molecular
Probes, Carlsbad, CA) at room temperature for 1 h.
Immunofluorescence images were acquired using an
inverted fluorescent microscope Zeiss Axiovert 200 M
(Carl Zeiss, Thornwood, NY) (×200).
Thioflavin S staining
After being transferred to 30 % sucrose solutions, brains
were cut into 30-μm sections by using a cryostat micro-
tome (Leica CM 1850; Leica Microsystems, Seoul,
Korea). After washes in distilled water for 5 min, the
brain sections were transferred to gelatin-coated slices
and placed in 1 % thioflavin S for 5 min. After this, the
brain sections were washed in distilled water then dehy-
drated through ascending grades of ethanol, 50, 70, 90,
and 100 % ethanol for 2 min in each grade. The sections
were then mounted in a mounting medium (Fluoromount™
Aqueous Mounting Medium, Sigma, St Louis, MO, USA).
The thioflavin S staining was examined using a fluores-
cence microscope (×100).
DAPI/TUNEL assay
The terminal deoxynucleotidyl transferase (TdT)-mediated
dUTP-biotin nick end-labeling (TUNEL) assays were
performed by using the in situ cell death detection kit
(Roche Diagnostics GmbH, Mannheim, Germany) ac-
cording to the manufacturer’s instructions. TUNEL
mixture was added onto tissue sections and incubated
in a humidified chamber for 60 min at 37 °C. After
each step, the tissue sections were rinsed twice with
PBS (pH 7.4). For DAPI staining, tissue sections were
incubated for 30 min at room temperature in the
dark. The cells were then observed through a fluores-
cence microscope Zeiss Axiovert 200 M (Carl Zeiss,
Thornwood, NY). The total number of cells in the
given area was determined by using DAPI nuclear
staining. The apoptotic bodies (TUNEL-stained cells)
were identified under a fluorescence microscope (×200)
containing green-colored nuclei. The quantity of apoptotic
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cells per high-power field (visible apoptotic cells/HPE).
Measurement of Aβ1–42
Lysates of brain tissue were obtained through protein
extraction buffer containing protease inhibitor. Aβ1–42
levels were determined using each specific ELISA Kit
(Immuno-Biological Laboratories Co., Ltd., Takasaki-Shi,
Gunma, Japan). Protein was extracted from brain tissues
(hippocampus regions), cultured astrocytes, and micro-
glial BV-2 cells using protein extraction buffer (PRO-
PREPTM, Intron Biotechnology, Korea), incubated on
ice for 1 h and centrifuged at 13,000g for 15 min at 4 °C.
In brief, 100 μl of sample was added into a precoated
plate and incubated overnight at 4 °C. After washing
each well of the precoated plate with a washing buffer,
100 μl of labeled antibody solution was added, and the
mixture was incubated for 1 h at 4 °C in the dark. After
washing, chromogen was added, and the mixture was
incubated for 30 min at room temperature in the dark.
Finally, the resulting color was assayed at 450 nm
using a microplate absorbance reader (Sunrise™, Tecan,
Switzerland) after adding stop solution.
Assay of β- and γ-secretase activities
β- and γ-secretase activity in mice brains was deter-
mined using a commercially available β- and γ-secretase
activity kit (Abcam, Inc, Cambridge, MA, USA). Protein
was extracted from brain tissues (hippocampus regions)
using protein extraction buffer (PRO-PREP™, Intron
Biotechnology, Korea), incubated on ice for 1 h, and
centrifuged at 13,000g for 15 min at 4 °C. The super-
natant was collected. A total of 50 μl of sample (total
protein 100 μg) was added to each well followed by
50 μl of ×2 reaction buffer and 2 μl of β-secretase sub-
strate incubated in the dark at 37 °C for 2 h. Fluores-
cence was read at excitation and emission wavelengths
of 355 and 510 nm, respectively, using a Fluostar
Galaxy fluorimeter (BMG Lab Technologies, Offenburg,
Germany) with Felix software (BMG Lab Technologies,
Offenburg, Germany). β- and γ-secretase activity is propor-
tional to the fluorimetric reaction and is expressed as
nanomole per milligram of protein per minute.
Nuclear extraction and gel mobility shift assay
Gel mobility shift assay was conducted using a slight
modification of a previously described method [28]. In
brief, 10 μg of nuclear protein of astrocytes was incu-
bated in 25 μL of the total volume of incubation buffer
(10 mmol/L Tris, pH 7.5, 100 mmol/L NaCl, 1 mmol/L
dithiothreitol, 4 % glycerol, 80 mg/L salmon sperm
DNA) at 4 °C for 15 min followed by another 20-min
incubation with 9.25 mBq [γ-32P] ATP-labeled oligo-
nucleotide containing the NF-κB-binding site at roomtemperature. The DNA protein-binding complex was
electrophoretically resolved on a 6 % nondenatured
polyacrylamide gel at 150 volts for 90 min. The gels
were dried and autoradiographed using Kodak MR
film at −80 °C overnight.
Pull-down assay
Melittin was conjugated with Epoxy-activated sepharose
6B (Sigma, St Louis, Missouri, United States). BV (1 mg)
was dissolved in 1 mL of coupling buffer (0.1 M
NaHCO3 and 0.5 M NaCl, pH 11). The Epoxy-activated
sepharose 6B was swelled and washed in 1 mM of HCl
on a sintered glass filter, then washed with a coupling
buffer. Epoxy-activated sepharose 6B beads were added
to the melittin containing coupling buffer and incubated
at 4 °C for overnight. After washing, unoccupied binding
sites were blocked with 1 M ethanolamine at 4 °C over-
night. The melittin-conjugated sepharose 6B was washed
with three cycles of alternating pH wash buffers (buffer 1;
0.1 M acetate and 0.5 M NaCl, pH 4; buffer 2; 0.1 M Tris-
HCl and 0.5 M NaCl, pH 8). Melittin-conjugated beads
were then equilibrated with a binding buffer (0.05 M Tris-
HCl and 0.15 M NaCl, pH 7.5). The control unconjugated
Epoxy-activated sepharose 6B beads were prepared as de-
scribed above with the absence of melittin. BV-2 cell lysates
were prepared in a lysis buffer of PRO-PREBP. The cell ly-
sates (1 mg of protein) were mixed with 20 μl of melittin-
conjugated sepharose 6B or sepharose 6B at 4 °C overnight.
The beads were then washed three times with TBST. The
bound proteins were eluted with SDS-loading buffer. The
proteins were then resolved by SDS-PAGE followed by im-
munoblotting with antibodies against p50 (1:1000, Santa
Cruz Biotechnology Inc. Santa Cruz, CA, USA).
Molecular modeling
Docking studies between melittin and p50 of NF-κB sub-
unit were performed using Autodock VINA [29]. Three-
dimensional structures of the NF-κB-DNA complexes
were retrieved from the Protein Data Bank (PDB codes;
1VKX), and melittin was retrieved from the PDB (PDB
codes; 2MLT). Starting from the co-crystallized com-
plexes, the NF-κB p50 monomer chain (p50 from
1VKX), melittin (melittin from 2MLT) for docking, were
prepared using Maestro graphical interface. The grid
box was centered on the p50 monomer, and the size of
the grid box was adjusted to include the whole mono-
mer. Docking experiments were performed at various
exhaustiveness values of the default, 16, 24, 32, 40, and
60. Molecular graphics for the best binding model were
generated using Discovery Studio Visualizer 2.0.
Western blotting
The hippocampus tissues, treated astrocytes, and micro-
glial BV-2 cells were homogenized with lysis buffer
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ice for 30 min, and centrifuged at 13,000g for 15 min at
4 °C. Cytosol protein was extracted using buffer A
(50 mM HEPES, pH 7.4, 10 mM KCl, 1 mM EDTA,
1 mM EGTA, 1 mM dithiothreitol, 0.1 mg/ml PMSF,
1 μg/ml pepstatin A, 1 mg/ml leupeptin, 10 μg/ml soy-
bean trypsin inhibitor, 10 μg/ml aprotinin, and 0.5 %
Nonidet P-40), incubated on ice for 10–15 min, and cen-
trifuged at 6000g for 10 min at 4 °C. This supernatant is
cytosol extract. Buffer C (buffer A + 10 % glycerol and
400 mM KCl) was added to the pellet, incubated on ice
for 30 min, and centrifuged at 13,000g for 15 min at
4 °C. This supernatant is nuclear extract. An equal
amount of total protein (40 μg) was resolved on 6–
15 % sodium dodecyl sulfate polyacrylamide gel and
then transferred to a nitrocellulose membrane (Hybond
ECL; Amersham Pharmacia Biotech, Piscataway, NJ,
USA). The membranes were blocked for 1 h in 5 % skim
milk solution and incubated overnight at 4 °C with spe-
cific antibodies. To detect target proteins, specific anti-
bodies against APP, iNOS (1:1000, Novus Biologicals,
Inc., Littleton), BACE1, IBA-1 (1:1000, Abcam, Inc.,
Cambridge, MA, USA), COX-2 (1:1000, Cell Signaling
Technology, Inc., Beverly, MA, USA), GFAP, p50, p65,
IκB, phospho-IκB, β-actin, and Histone H1 (1:1000, Santa
Cruz Biotechnology Inc. Santa Cruz, CA, USA) were
used. The blots were then incubated with the corre-
sponding conjugated goat anti-rabbit or goat anti-mouse
or donkey anti-goat IgG-horseradish peroxidase (HRP)
(1:5000; Santa Cruz Biotechnology Inc. Santa Cruz, CA,
USA) secondary antibodies. Immunoreactive proteins
were detected with an enhanced chemiluminescence
western blotting detection system. The relative density of
the protein bands was scanned by densitometry using
MyImage (SLB, Seoul, Korea) and quantified by Labworks
4.0 software (UVP Inc., Upland, CA, USA).
Statistical analysis
Measurement of the image data used ImageJ (Wayne
Rasband, National Institutes of Health, Bethesda, MD).
Statistical analysis of the data was carried out using
analysis of variance (ANOVA) for repeated measures
followed by Dunnett’s post-hoc analysis using GraphPad
Prism 4 software (Version 4.03, GraphPad software, Inc.,
La Jolla, USA).
Results
Inhibitory effect of BV on LPS-induced memory defects
Seven- to eight-week old ICR mice were administered
with LPS (2.5 mg/kg) for 7 days to study whether BV
could improve memory in LPS-induced AD mice. We
used the Morris water maze and passive avoidance per-
formance tests. The mice were trained for three trials
per day. Control mice took short escape latency to get tothe platform, but LPS-treated mice arrived at the loca-
tion of the platform more slowly than the control mice,
suggesting that the memory deficiency could be induced
by LPS as reported previously [30]. BV-treated mice
however, exhibited shorter escape latency than LPS-
treated mice. BV-treated mice with a higher dose
showed shorter escape latency than BV-treated mice
with a lower dose (Fig. 1b). BV-treated mice also showed
shorter escape distance compared to LPS-treated mice
(Fig. 1c). However, there was no significant difference in
average velocity between LPS-treated mice and BV-
treated mice (Fig. 1d). Next, we examined the passive
avoidance performance test 1 day after the Morris water
maze test. Stay time in the white chamber indicated
maintenance of memory capacity. LPS-treated mice
(351.1 ± 72.9 s) stayed for a shorter time than control
mice (502.0 ± 52.7 s). BV-treated mice (BV 0.8 μg/kg;
495.6 ± 46.2 s, BV 1.6 μg/kg; 454.6 ± 73.3 s) stayed for a
longer time than LPS-treated mice but shorter than
control mice demonstrating memory recovery effect
(Fig. 1e).
Inhibitory effect of BV in LPS-induced amyloidogenesis
and Aβ accumulation
AD is known to be correlated with accumulation of Aβ
peptides. Therefore, we examined whether BV reduced
LPS-induced Aβ accumulation and amyloidogenesis, and
thus recovery memory function. Thioflavin S staining is
dyed with beta sheet-rich structures of Aβ. This thiofla-
vin S staining was used for detection of Aβ accumula-
tion. The higher accumulation of Aβ was seen in the
brain of LPS-treated mice; however, lower accumulation
of Aβ was seen in the BV-treated mice brain (Fig. 2a).
We also used immunohistochemistry for detection of Aβ
expression and acquired the same results as thioflavin S
staining (Fig. 2b). We analyzed the expression of APP
and BACE1 by western blotting. LPS-treated mice in-
creased the expression of these proteins, but BV-treated
mice showed decreased expressions (Fig. 2c). To clarify
how amyloidogenesis was reduced by BV, we analyzed
the amount of Aβ1−42 level and β- and γ-secretase activ-
ities in whole brain. The level of Aβ1−42 and activities of
β- and γ-secretase were significantly increased in LPS-
treated mice brain, while these level and activities were
decreased in BV-treated mice brain (Fig. 2d–f ). Because
the activation of astrocytes is implicated in the activation
of β-secretase, we investigated whether the numbers of
astrocytes (GFAP-positive cells) and the accumulation of
Aβ are concomitantly increased by LPS, and whether BV
reduces astrocytes activation, thereby reducing Aβ1-42
levels. The immunoreactive cells for both GFAP and
Aβ1-42 were identified using a double immunofluores-
cence method. The co-reactive cell number for both
markers was increased by LPS, but was lowered by BV
Fig. 2 Inhibitory effect of BV on LPS-induced Aβ accumulation and amyloidogenesis in mice brain. Thioflavin S staining for detection of Aβ
accumulation that represents the arrow in the graph (a). Immunostaining of Aβ protein in the hippocampus was performed in 30-μm-thick
sections of mice brain with anti-Aβ1-42 primary antibody and the biotinylated secondary antibody (b). The expression of APP and BACE1
were detected by western blotting using specific antibodies in the mice brain. Each blot is representative of three experiments (c). The
levels of Aβ1-42 in mice brain were measured by ELISA (d). Inhibitory effect of BV on LPS-induced alteration in secretase activity. The activity
of β- and γ-secretase in mice brain were investigated using assay kit (e, f). Values are presented as mean ± S.E. from eight mice. #p < 0.05
compare to control, *p < 0.05 compared to LPS
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microglia cells. The double positive cell number for Aβ
accumulation in microglia cells (IBA-1-positive cells)
was increased by LPS, which was also lowered by BV
treatment (Fig. 3b).
Inhibitory effect of BV on LPS-induced neuronal cell death
and neuroinflammation
To observe death of brain cells, we used the DAPI/
TUNEL assay. Apoptosis (%) was defined as the percent-
age of the number of TUNEL-positive cells per surface
of unit. TUNEL-stained brain cells were more in LPS-
treated mice brain (61.0±1.8) compared to control
(8.6±1.4) and BV-treated mice brain. BV-treated mice
brain values were 26.6±4.1 (0.8 μg/kg), and 22.3±1.7
(1.6 μg/kg), respectively (Fig. 4).Activated NF-κB by LPS can trigger neuroinflamma-
tion in neuronal cells through activation of inflammatory
cells such as astrocytes and microglia cells. To confirm
activation of astrocytes and microglia cells, we used the
immunohistochemistry and western blotting to detect
the expression of GFAP (a marker of astrocyte activation),
IBA-1 (a marker of microglia cell activation), iNOS, and
COX-2 in the brain. The results showed that LPS-treated
mice brain increased expression of these proteins in
comparison with control; however, expression of these
proteins was decreased in BV-treated mice brain
(Fig. 5a, b).
Inhibitory effect of BV on LPS-induced NF-κB activation
To determine whether BV is able to inhibit LPS-induced
DNA-binding activity of NF-κB in the mice model,
Fig. 3 Inhibitory effect of BV on LPS-induced expression of Aβ1-42 in both GFAP and IBA-1-positive mice brain. Staining was performed in 30-μm-thick
sections of mice brain. Confocal microscope observation was performed as described in the Methods section. Immunostaining of GFAP (green) and
Aβ1−42 (red) protein in the hippocampus was performed with specific primary antibodies, and fluorescence was developed using Alexa 488-conjugated
anti-goat and Alexa 568-conjugated anti-rabbit secondary antibodies (a). IBA-1 (red) and Aβ1−42 (green) protein in the hippocampus was performed
with specific primary antibodies, and fluorescence was developed using Alexa 488-conjugated anti-mouse and Alexa 568-conjugated anti-rabbit
secondary antibodies (b). Values are presented as mean ± S.E. from eight mice. #p < 0.05 compared to control, *p < 0.05 compared to LPS
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assayed for NF-κB DNA-binding activity by EMSA
(Fig. 6a). LPS significantly induced NF-κB; however, its
activity was effectively blocked by BV. When treated
with LPS, we found that NF-κB proteins (p50 and p65)
were translocated to the nucleus, and IκB was phosphor-
ylated, while BV remarkably inhibited LPS-induced
translocation of p50 and p65 in the nucleus as well as
IκB phosphorylation in a dose-dependent manner in
mice brain (Fig. 6b).
Interaction between melittin and p50 of the NF-κB
subunit
To investigate whether the inhibitory effect of BV on ac-
tivity due to direct binding of melittin, a major compo-
nent of BV (Fig. 6c), and p50, a subunit of NF-κB, weperformed a pull-down assay and molecular docking
experiment between melittin and p50 of the NF-κB sub-
unit using melittin-sepharose 4B beads. The binding of
melittin to p50 was then detected by immunoblotting
with an anti-p50 antibody. The results indicated that
melittin interacted with cell lysates containing p50 from
microglial BV-2 cells as well as recombinant p50 protein
(Fig. 6d). To identity the binding site of p50 to melittin,
we performed computational docking experiments with
melittin and p50. The binding study was performed
using Autodock Vina software and showed that melittin
binded near to the C-terminus of p50 (melittin binds to
Tyr387, Vol388, Pro39, Lys392, Thr424, Pro427, Lys428,
Thr522, Ser524, and Phe525 of p50) where nuclear
localization signal (NLS) is located in this specific p50
(Fig. 6e).
Fig. 4 Inhibitory effect of BV on LPS-induced cell death. DAPI/TUNEL assay for detection of apoptotic cell death in the hippocampal DG zone was
performed in 30-μm-thick sections of mice brain (a). Apoptosis (%) was defined as the percentage of the number of TUNEL-positive cells
per surface of unit (b). Values are mean ± S.E. (n = 8). #p < 0.05 compared to control, *p < 0.05 compared to LPS
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neuroinflammatory responses in astrocytes and
microglia cells
To find anti-amyloidogenesis of BV in primary cultured
astrocytes (Fig. 7a) and microglial BV-2 cells, both
cells were treated with 1 μg/mL of LPS and 0.5, 1 and
2 μg/mL of BV (Fig. 7b) and then detected APP and
BACE1 expression by western blotting. LPS-treated
cells increased expression of APP and BACE1 than
control, but BV-treated cells clearly decreased expres-
sion of APP and BACE1 than LPS-treated cells. More-
over, the LPS-induced Aβ1-42 level was decreased by
the treatment of BV determined by ELISA (Fig. 7c, d).
We also discovered that BV inhibited LPS-induced
NF-κB activity, translocation of NF-κB proteins (p50
and p65) to the nucleus and IκB phosphorylation in
both cells (Fig. 7g, h). The expression of inflammatory
proteins (iNOS, COX-2, GFAP, and IBA-1) was also
detected by western blotting using specific antibodies.
The BV attenuated LPS-induced increased expression
of inflammatory proteins in a dose-dependent manner
(Fig. 7i, j). On the same principle as brain sections, we
detected double immunofluorescence in both cells by
confocal microscope analysis. Co-expression of GFAP
(astrocytes marker) and Aβ1-42 was increased by LPS
but was decreased by BV treatment in primary cul-
tured astrocytes (Fig. 8a). Co-expression of IBA-1
(microglia cell marker) and Aβ1-42 in microglial BV-2
cells showed the same results as primary cultured as-
trocytes (Fig. 8b).Discussion
Increasing Aβ accumulation and neuroinflammation in
the brain contributes to the onset development of AD
by causing neuronal cell death [2, 3]. Our study showed
that BV prevented LPS-induced memory impairment.
Significantly, BV ameliorated LPS-mediated amyloido-
genesis and neuroinflammatory reactions in the brain as
well as cultured inflammatory neuronal cells, thus mem-
ory improvement through direct inhibition of NF-κB.
These data indicate that BV could be useful for treat-
ment of AD. Our previous study revealed that LPS injec-
tion caused amyloidogenesis and memory loss in mice
brain through NF-κB activation [30]. The aging process
is a potential contributor to the accumulation of Aβ and
other risk factors of AD. Recent study also demonstrated
that the neuroinflammatory response to surgery causes
postoperative cognitive dysfunction via the activation of
AD pathogenic mechanisms such as gliosis, microgliosis,
astrogliosis, enhanced production of Aβ, and τ protein
phosphorylation in old subjects [31]. For these reasons,
the elder mice are more effective for the study of AD
pathology. But, in the present study, we used seven- to
eight-week old mice because we already showed that the
AD pathogical changes were found in 7–10 weeks after
treatment of LPS (2.5 mg/kg) [26, 30, 32, 33]. NF-κB ac-
tivates the transcription of APP, BACE1, and γ-secretase
and therefore increases generation of Aβ because NF-κB
is a transcription factor of these genes [13, 34]. Our re-
cent studies demonstrated that melittin, a major compo-
nent of BV, inhibited LPS-induced NF-κB activation by
Fig. 5 Inhibitory effect of BV on LPS-induced brain cell activation and neuroinflammation. Immunostaining of GFAP, IBA-1, COX-2, and iNOS
proteins in the hippocampus were performed in 30-μm-thick sections of mice brain with specific primary antibodies and the biotinylated
secondary antibodies (n = 8) (a). The expression of GFAP, IBA-1, COX-2, and iNOS were detected by western blotting using specific antibodies in
the mice brain. Each blot is representative of three experiments (b)
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sulfhydryl residue of p50 or IKK [23, 24]. Our present
study also showed that BV reduced LPS-induced DNA-
binding activities of NF-κB, interrupting p50 and p65
translocation through preventing IκB phosphorylation in
mice brain as well as cultured astrocytes and microglia
cells. Thus, the inhibiting effect of BV on NF-κB activity
could result in anti-amyloidogenesis. Similar to the
present study, our previous studies also showed that
thiacremonone and 4-O-methylhonokiol inhibited tran-
scriptional and DNA-binding activity of NF-κB via in-
hibition of IκB degradation as well as p50 and p65
translocation into the nucleus of the brain and cultured
astrocytes and microglial BV-2 cells, and thus these com-
pounds enhance memory function by anti-amyloidogenic
effects [14, 30]. Huang X. et al. showed inhibition of
the accumulation of Aβ through inhibition of IKK ac-
tivation, IκB degradation, and the subsequent NF-κB
activation [35]. These results demonstrated that direct
binding of melittin, a major component of BV, to p50
results in the inhibitory effect of BV on NF-κB, andinhibition of NF-κB could be significant for the anti-
amyloidogenic effect of BV.
Anti-amyloidogenesis effect of BV was associated with
decreases of expression of inflammatory response genes
such as iNOS and COX-2. Guo et al. demonstrated that
neuroinflammation plays an important role in the
process of amyloid deposition [36]. Deng et al. also
showed that LPS-induced neuroinflammation was asso-
ciated with amyloidogenesis in adult rat brains [37].
Neuroinflammation is associated with a broad spectrum
of neurodegenerative diseases including AD [38]. It has
been shown that there are increases in markers of neu-
roinflammation in AD patients’ brain [39]. LPS-induced
systemic inflammation has been shown to impair neur-
onal cells in animal models for AD [9, 30, 40]. Actually,
LPS kills neurons after treatment of high concentrations
and long-term periods of LPS. In fact, the induction of
neuroinflammation or brain cell death depends on the
experimental injection method, concentration, and pe-
riods of LPS treatment. Recent study demonstrated that
long-term sustainable (16th day after LPS injections)
Fig. 6 Inhibitory effect of BV on LPS-induced NF-κB DNA-binding activity and on NF-κB-related protein in mice brain. Activation of NF-κB was
investigated using EMSA as described in the Methods section. Nuclear extracts were subjected to DNA-binding reaction with 32P end-labeled
oligonucleotide specific to NF-κB. Specific DNA binding of the NF-κB complex is indicated by an arrow (a). The expression of IκB, p-IκB, p50,
and p65 were detected by western blotting using specific antibodies in the mice brain. Each blot is representative of three experiments (b).
Structural interaction between melittin and p50 of NF-κB subunit. Melittin structure is c. Pull-down assay identifies an interaction between the
melittin and p50. Melittin was conjugated with melittin-activated Sepharose 6B (d). The docking model of melittin with p50 is as described in
the Materials and Methods section (e)
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flammation by LPS (10 mg/kg) was associated with brain
cell and microvasculature injury in the sub-region of the
hippocampus which ultimately likely results in brain
functional impairment [41]. Lee et al. demonstrated that
two different doses of LPS (0.25 or 0.75 mg/kg/day for
7 days) could induce memory dysfunction and amyloido-
genesis but did not show significant difference between
the two doses (Y.J. Lee, J.A. Kim and J.T. Hong, unpub-
lished observations). We also observed the low concen-
trations of LPS (0.25 mg/kg/day) for 3 to 7 days and
found that they were really not much different between
3 and 7 days [9]. It has also been demonstrated that sev-
eral compounds such as 4-O-methylhonokiol, obovatol,
and thiacremonone showed anti-amyloidogenesis and
memory-recovering effect in LPS (0.25 mg/kg/day for
7 days)-induced amyloidogenesis and memory loss[14, 30, 32]. Based on these previous data, we used
2.5 mg/kg for 7 days for the treatment of mice for
this present study. Sheng et al. showed that LPS-
induced neuroinflammation of APPswe transgenic mice
increases levels of APP and Aβ and causes the accumula-
tion of Aβ within the cell bodies of neurons. Neuroin-
flammation can be caused by excessive activation of
astrocytes and microglia cells. Lee et al. showed that acti-
vated astrocytes and microglial BV-2 cells by LPS pro-
duced TNF-α, IL-1β, iNOS, and COX-2 in cultured
astrocytes and microglial BV-2 cells [42]. It was also re-
ported that the expression of beta APP was elevated by
activation of astrocytes and microglia cells in primary
cultures of a cerebral cortex from a newborn rat [43].
Thus, inhibition of LPS-induced of neuroinflammation
by inactivation of astrocytes and microglia cells by BV
could be associated with anti-amyloidogenesis of BV.
Fig. 7 The expression of APP and BACE1 in astrocyte primary cells (a) and microglia BV-2 cells (b) were detected by western blotting using
specific antibodies. Inhibitory effect of BV on LPS-induced NF-κB DNA-binding activity and on NF-κB-related protein in astrocyte primary
cells (c) and microglia BV-2 cells (d). Activation of NF-κB was investigated using EMSA as described in the Methods section. Nuclear extracts
were subjected to DNA-binding reaction with 32P end-labeled oligonucleotide specific to NF-κB. Specific DNA binding of the NF-κB complex is
indicated by an arrow. The levels of Aβ1-42 in astrocyte primary cells (e) and microglia BV-2 cells (f) were measured by ELISA (n = 3). Values are
presented as mean ± S.E. of the three independent experiments performed in triplicate. #p < 0.05 compared to control, *p < 0.05 compared to
LPS. The expression of IκB, p-IκB, p50, and p65 in astrocyte primary cells (g) and microglia BV-2 cells (h) was detected by western blotting using
specific antibodies. The expression of GFAP, IBA-1, COX-2, and iNOS in astrocyte primary cells (i) and microglia BV-2 cells (j) were detected by
western blotting using specific antibodies. Each blot is representative of three experiments
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tion of NF-κB [44]. Rolova et al. showed that cultured
microglia deficient for the gene (Nfkb1) encoding p50
subunit shows reduced induction of proinflammatory
mediators, increased expression of anti-inflammatory
genes in response to LPS exposure in microglia cells.
They also showed that p50 NF-κB−/−mice (Nfkb1-defi-
cient mice) crossed with transgenic Alzheimer mice
(APdE9 transgenic mice) reduced Aβ levels [45]. It was
proved that NF-κB is directly involved in the regulation
of GFAP gene expression in cultured primary human
brain astrocytes [46]. Webster et al. showed decrease in
translocation of p65 in genetic knock-down in vitro via
siRNA, or in vivo P2Y12, microglial purinergic receptortransgenic mice (P2Y12
−/−, P2Y12
+/−) [47]. Wang et al. also
showed that 3-N-butylphthalide (NBP) has been reported
to attenuate astroglial activation and exert neuroprotective
effects in AD transgenic mice by attenuation of Aβ-
induced activation of astrocytes and neuroinflammation
via inhibition of the NF-κB signaling pathway [48, 49].
Our various AD animal models have shown that activity
of NF-κB increased activation of both cells [14, 30, 50, 51].
These data suggest that blocking of NF-κB is also signifi-
cant for inactivation of astrocytes and microglia cells for
preventing neuroinflammation and amyloidogenesis.
The way to inhibit NF-κB by BV is important for the
basic principle for inhibition of NF-κB. In this regard, it
is noteworthy that BV binds to protein of p50, a subunit
Fig. 8 The cultured astrocytes were incubated with anti-GFAP (green) and anti- Aβ1−42 (red) primary antibodies, and microglial BV-2 cells were
incubated with anti-IBA-1 (green) and anti- Aβ1−42 (red) primary antibodies. Fluorescence was developed using Alexa 488-conjugated anti-mouse
and goat and Alexa 568-conjugated anti-rabbit secondary antibodies (a) and (b). Values are presented as mean ± S.E. from three mice. #p < 0.05
compared to control, *p < 0.05 compared to LPS
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model. 7,8-dihydroxy-4-methylcoumarin (7,8-DHMC),
5,7-dihydroxy-4-methylcoumarin (5,7-DHMC) and gallic
acid have shown that direct binding to NF-κB subunits
could result in inhibition of NF-κB activities. 7,8-DHMC
and 5,7-DHMC form three hydrogen bonds with DNA-
binding region (DBR), but gallic acid makes five hydro-
gen bonds with DBR [52]. We previously found that the
inhibitory effect of BV on NF-κB due to direct binding
of melittin, a major component of BV to p50 subunit
(DNA-binding site) of NF-κB, was determined by surface
plasmon resonance analyzer [23]. Our present study
confirmed that melittin binds to p50 of the NF-κB sub-
unit through the docking model and pull-down assay.
However, unlike previous findings, the present study
showed that melittin directly binds to the C-terminus of
p50 (melittin binds to Tyr387, Vol388, Pro39, Lys392,
Thr424, Pro427, Lys428, Thr522, Ser524, and Phe525 of
p50) where nuclear localization sequence (NLS) is lo-
cated. It was reported that blocking NLS is importantfor inhibition of NF-κB activity by suppressing nuclear
translocation of p50 [53]. Melittin also binds to the
dimerization interface of p50 (melittin binds to Arg552,
Aso554, Glu565, Tyr567, Leu569, His604, Arg605,
Phe607, Val610, and Lys612 of p50); therefore, melittin
potentially prevents p50-p65 dimerization, and melittin
also can interrupt the nuclear translocation of p50.
These data indicated that BV could directly bind to
NF-κB (p50), thus inhibiting NF-κB activity.
BV has demonstrated the inhibitory effect on rheuma-
toid arthritis (RA) in a carrageenan rat model and a rat
model of chronic adjuvant-induced arthritis, amyo-
trophic lateral sclerosis (ALS) in a hSOD1G93A mutant
mice model, and Parkinson’s disease (PD) in a 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice
model through control of NF-κB activation [23, 54, 55].
BV also has shown the cancer cell growth inhibitory effect
via inactivation of NF-κB in non-small cell lung cancer
(NSCLS) cells and human prostate cancer cells (LNCaP,
DU145, and PC-3) [56, 57]. Moreover, BV and melittin
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aortic vascular smooth muscle cell (VSMC) via suppres-
sions of NF-κB activation [58]. These studies showed that
BV could be useful for treatment of several diseases
through inhibition of NF-κB activation. To conclude, our
present data indicate that BV could be effective for treat-
ment and/or prevention of the development of diseases
such as AD through anti-amyloidogenesis and anti-
inflammatory responses by inhibiting NF-κB activation.
Conclusions
We demonstrated that BV decreased amyloidogenesis
and neuroinflammation. This observation was confirmed
by expression of GFAP, IBA-1, COX-2, and iNOS. These
proteins were decreased in BV injection groups. We also
observed that BV has effect on the inhibition of NF-κB
activation through expression of IκB, phospho-IκB, p50,
and p65. Especially, melittin, a major component of BV,
directly binds to the C-terminus of p50 where NLS is
located, so they interrupt translocation of NF-κB. There-
fore, BV can be used as a treatment of amyloidogenesis
and neuroinflammation disease such as AD and disease
by NF-κB activation.
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